1st Quarter - Report

THE MCMANUS GROUP for ROCHE DIAGNOSTICS

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Foreign entity interest: 100% ownership by F. Hoffman-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, SUI

LobbyistCovered position, as disclosed
JOHN MCMANUS —
ALEX WHALEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5269 (119th), H.R. 5343 (119th), S. 1717 (119th)

Trade (domestic/foreign) TRD

Issues related to global trade and tariffs.

Foreign entity interest: 100% ownership by F. Hoffman-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, SUI

LobbyistCovered position, as disclosed
JOHN MCMANUS —
ALEX WHALEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.